Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.67 |
| ▸ | PPARA | Q07869 | 5/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041193 | 0.99 | PPARG (0.66) | PPARGPPARAJAK2JAK1TYK2 | |
| Lithium Ion SCHEMBL7041189 | 0.90 | PPARG (0.77) | PPARGPPARAJAK2JAK1TYK2 | |
| SCHEMBL7037060 | 0.90 | PPARG (0.62) | PPARGPPARAJAK2JAK1TYK2 | |
| SCHEMBL7037849 | 0.88 | PPARG (0.66) | PPARGPPARALMNAHTTSMN1; SMN2 | |
| SCHEMBL7038131 | 0.87 | PPARG (0.64) | PPARGPPARALMNAHTTSMN1; SMN2 | |
| SCHEMBL7040832 | 0.86 | PPARG (0.81) | PPARGPPARASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7034817 | 0.85 | PPARG (0.80) | PPARGPPARASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7041887 | 0.83 | PPARG (0.69) | PPARGPPARASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7040279 | 0.83 | PPARG (0.59) | PPARGPPARASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7041258 | 0.83 | PPARG (0.71) | PPARGPPARALMNAHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | claimed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885JAK2 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.